Pharma - The Round-up – 02 October 2018
News in brief from around the world… Regulators in the US and EU have halted imports from a Chinese pharma company after a summer of investigations and India’s competition regulator has penalised a global healthcare equipment group.
Pharma - The Round-up – 25 September 2018
News in brief from around the world… The past week has seen three US hospitals and one physician penalised for violating the privacy protections of the US Health Insurance Portability and Accountability Act. There have also been further efforts to bring down drug costs in the US senate and the development of a closer relationship between the country’s regulatory agency and its Portuguese counterparts
Pharma - The Round-up – 18 September 2018
News in brief from around the world… The past week has seen China approve Takeda’s £46 billion acquisition of Shire and Novartis sell off parts of its Sandoz portfolios to India’s Aurobindo. Meanwhile Gwyneth Paltrow’s Goop has settled a false advertising suit, the EMA and FDA have published the findings from a carcinogen study, and the British Medical Journal has criticised clinical trials compliance.
Pharma - The Round-up – 11 September 2018
News in brief from around the world… Simmons & Simmons and Pepper Hamilton have both made lateral hires in the past week, while France has introduced new measures to encourage the biosimilar prescriptions and companies in the US have lobbied for more clarity on healthcare communications.
Pharma - The Round-up – 04 September 2018
News in brief from around the world… Opioid maker Purdue Pharma has reached a settlement with claimants in a patent suit this week, meanwhile two companies have been blocked from selling allegedly dangerous erectile dysfunction drugs by the FDA.
Pharma - The Round-up – 28 August 2018
News in brief from around the world… In the past week, a new Dutch lobbying group has launched a competition case against Leadiant Biosciences while a court in Singapore has issued a freezing order over assets linked to a defunct Chinese medical device company. Meanwhile, the US has approved the first drugs under its Competitive Generic Therapy pathway and Morgan Lewis has added a new IP partner in California.